User profiles for E. Haavardsholm

Espen A. Haavardsholm

Professor (MD PhD)
Verified email at medisin.uio.no
Cited by 16185

Physical therapy interventions for patients with osteoarthritis of the knee: an overview of systematic reviews

…, A Christie, RH Moe, E Haavardsholm… - Physical …, 2008 - academic.oup.com
Patients with osteoarthritis of the knee are commonly treated by physical therapists. Practice
should be informed by updated evidence from systematic reviews. The purpose of this …

Effectiveness of nonpharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews

…, KT Dahm, RH Moe, EA Haavardsholm… - Physical …, 2007 - academic.oup.com
Conclusions based on systematic reviews of randomized controlled trials are considered to
provide the highest level of evidence about the effectiveness of an intervention. This …

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …

…, GL Goll, M Lorentzen, N Bolstad, EA Haavardsholm… - The Lancet, 2017 - thelancet.com
… The computer-generated randomised allocation sequence was imported into the electronic
case report form (eCRF) system (Viedoc; version 3.20) and made available exclusively to the …

EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis

…, K Forslind, W Grassi, EA Haavardsholm… - Annals of the …, 2013 - ard.bmj.com
… Ten recommendations were produced, and the final wording of the propositions was
adjusted using e-mail exchange and at the closing meeting of the group. The recommendations, …

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

…, JE Gottenberg, EA Haavardsholm… - Annals of the …, 2023 - ard.bmj.com
Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management
recommendations addressing the most recent developments in the field. Methods An international …

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort …

…, G Grødeland, EA Haavardsholm… - The Lancet …, 2022 - thelancet.com
Background In rituximab-treated patients with rheumatoid arthritis, humoral and cellular immune
responses after two or three doses of SARS-CoV-2 vaccines are not well characterised. …

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10 …

…, GL Goll, S Ødegård, EA Haavardsholm… - Annals of the …, 2008 - ard.bmj.com
Objectives: New effective therapies with particularly good effect on joint destruction have
highlighted the need for reliable predictors of radiographic progression in rheumatoid arthritis (…

Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression

EA Haavardsholm, P Bøyesen, M Østergaard… - Annals of the …, 2008 - ard.bmj.com
Objectives: To examine the spectrum and severity of magnetic resonance imaging (MRI)
findings in patients with early rheumatoid arthritis (RA), and to investigate the predictive value of …

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial

EA Haavardsholm, AB Aga, IC Olsen, S Lillegraven… - bmj, 2016 - bmj.com
… yearly, but both the patient and the treating physician were blinded to the results, and the
treating physicians did not have access privileges to ultrasound data in the electronic case …

Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory …

…, TK Kvien, J Jahnsen, N Bolstad, EA Haavardsholm - Jama, 2021 - jamanetwork.com
e One patient had both a withdrawal from study prior to week 52 and a prolonged infusion
… Dr Haavardsholm reported receipt of personal fees from Pfizer, AbbVie, Celgene, Novartis, …